← All MEPs

Claudiu Manda

European Parliament · S&D · 🇷🇴 Romania

Term: since 18 July 2019

Participation in roll-call votes

58 % of the 2,540 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 100 % (19 / 19), presence 100 % (19 / 19) November 2019 : participation 83 % (15 / 18), presence 83 % (15 / 18) December 2019 : participation 83 % (5 / 6), presence 83 % (5 / 6) January 2020 : participation 83 % (10 / 12), presence 83 % (10 / 12) 2020 February 2020 : participation 75 % (6 / 8), presence 75 % (6 / 8) May 2020 : participation 98 % (53 / 54), presence 98 % (53 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 58 % (11 / 19), presence 58 % (11 / 19) September 2020 : participation 0 % (0 / 24), presence 0 % (0 / 24) October 2020 : participation 51 % (19 / 37), presence 51 % (19 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 97 % (30 / 31), presence 97 % (30 / 31) April 2021 : participation 100 % (81 / 81), presence 100 % (81 / 81) May 2021 : participation 96 % (25 / 26), presence 96 % (25 / 26) June 2021 : participation 79 % (23 / 29), presence 79 % (23 / 29) July 2021 : participation 59 % (16 / 27), presence 59 % (16 / 27) September 2021 : participation 74 % (14 / 19), presence 74 % (14 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 89 % (24 / 27), presence 89 % (24 / 27) December 2021 : participation 69 % (20 / 29), presence 69 % (20 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 92 % (34 / 37), presence 92 % (34 / 37) April 2022 : participation 0 % (0 / 22), presence 0 % (0 / 22) May 2022 : participation 9 % (8 / 88), presence 9 % (8 / 88) June 2022 : participation 0 % (0 / 46), presence 0 % (0 / 46) July 2022 : participation 0 % (0 / 31), presence 0 % (0 / 31) September 2022 : participation 0 % (0 / 25), presence 0 % (0 / 25) October 2022 : participation 44 % (14 / 32), presence 44 % (14 / 32) November 2022 : participation 97 % (37 / 38), presence 97 % (37 / 38) December 2022 : participation 72 % (13 / 18), presence 72 % (13 / 18) January 2023 : participation 0 % (0 / 16), presence 0 % (0 / 16) 2023 February 2023 : participation 48 % (14 / 29), presence 48 % (14 / 29) March 2023 : participation 62 % (18 / 29), presence 62 % (18 / 29) April 2023 : participation 0 % (0 / 24), presence 0 % (0 / 24) May 2023 : participation 87 % (81 / 93), presence 87 % (81 / 93) June 2023 : participation 28 % (11 / 40), presence 28 % (11 / 40) July 2023 : participation 0 % (0 / 40), presence 0 % (0 / 40) September 2023 : participation 0 % (0 / 27), presence 0 % (0 / 27) October 2023 : participation 95 % (38 / 40), presence 95 % (38 / 40) November 2023 : participation 75 % (40 / 53), presence 75 % (40 / 53) December 2023 : participation 70 % (28 / 40), presence 70 % (28 / 40) January 2024 : participation 100 % (49 / 49), presence 100 % (49 / 49) 2024 February 2024 : participation 84 % (53 / 63), presence 84 % (53 / 63) March 2024 : participation 0 % (0 / 50), presence 0 % (0 / 50) April 2024 : participation 54 % (115 / 213), presence 54 % (115 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 100 % (8 / 8), presence 100 % (8 / 8) October 2024 : participation 23 % (3 / 13), presence 23 % (3 / 13) November 2024 : participation 0 % (0 / 27), presence 0 % (0 / 27) December 2024 : participation 94 % (17 / 18), presence 94 % (17 / 18) January 2025 : participation 83 % (5 / 6), presence 83 % (5 / 6) 2025 February 2025 : participation 80 % (8 / 10), presence 80 % (8 / 10) March 2025 : participation 0 % (0 / 14), presence 0 % (0 / 14) April 2025 : participation 95 % (21 / 22), presence 95 % (21 / 22) May 2025 : participation 93 % (50 / 54), presence 93 % (50 / 54) June 2025 : participation 36 % (8 / 22), presence 36 % (8 / 22) July 2025 : participation 91 % (29 / 32), presence 91 % (29 / 32) September 2025 : participation 90 % (26 / 29), presence 90 % (26 / 29) October 2025 : participation 0 % (0 / 45), presence 0 % (0 / 45) November 2025 : participation 25 % (13 / 51), presence 25 % (13 / 51) December 2025 : participation 81 % (25 / 31), presence 81 % (25 / 31) January 2026 : participation 95 % (21 / 22), presence 95 % (21 / 22) 2026 February 2026 : participation 96 % (27 / 28), presence 96 % (27 / 28) March 2026 : participation 68 % (30 / 44), presence 68 % (30 / 44) April 2026 : participation 25 % (13 / 51), presence 25 % (13 / 51) May 2026 : participation 12 % (3 / 25), presence 12 % (3 / 25) June 2026 : participation 0 % (0 / 35), presence 0 % (0 / 35) July 2026 : participation 37 % (13 / 35), presence 37 % (13 / 35) September 2026 : participation 0 % (0 / 40), presence 0 % (0 / 40) October 2026 : participation 34 % (18 / 53), presence 34 % (18 / 53) November 2026 : participation 100 % (13 / 13), presence 100 % (13 / 13)

Their votes

2,540 votes

DateTextResultTheir vote
Implementation of the common commercial policy – annual report 2018 Absent
The Establishment of an EU Mechanism on Democracy, the Rule of Law and Fundamental Rights Absent
The European Year of Greener Cities 2022 Absent
COVID-19: EU coordination of health assessments and risk classification, and the consequences for Schengen and the single market Absent
The cultural recovery of Europe Absent
The draft Commission regulation amending Annexes II, III and IV to Regulation (EC) No 396/2005 as regards maximum residue levels for cycloxydim, flonicamid, haloxyfop, mandestrobin, mepiquat, Metschnikowia fructicola strain NRRL Y-27328 and prohexadione in or on certain products Absent
Measures for a sustainable rail market in view of the COVID-19 pandemic Absent
The humanitarian situation in Mozambique Absent
The case of Dr. Denis Mukwege in the Democratic Republic of the Congo (DRC) Absent
The situation in the Philippines, including the case of Maria Ressa Absent
Resolution on the situation in Russia: the poisoning of Alexei Navalny Absent
The situation in Belarus Absent
The preparation of the special European Council summit focusing on the dangerous escalation and the role of Turkey in the Eastern Mediterranean Absent
Report on the implementation of National Roma Integration Strategies: Combating negative attitudes towards people with Romani background in Europe Absent
Shortage of medicines - how to address an emerging problem Absent
Maximising the energy efficiency potential of the EU building stock Absent
A strategic approach to pharmaceuticals in the environment Absent
Determination of a clear risk of a serious breach by Poland of the rule of law Absent
Annual report on arms export Absent
Just Transition Fund Absent
Real Driving Emissions  (RDE) Absent
Annual implementing report on the EU association agreement with Georgia Absent
Carbon dioxide emissions from maritime transport: global data collection system for ship fuel oil consumption data Absent
Union Civil Protection Mechanism Absent
EU-African security cooperation in the Sahel region, West Africa and the Horn of Africa Absent
The EU’s role in protecting and restoring the world’s forests Absent
The conclusions of the extraordinary European Council meeting of 17-21 July 2020 For
Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or pent coronavirus disease For
Emission limits and type-approval for internal combustion engines for non-road mobile machinery: transitional provisions in order to address the impact of COVID-19 crisis For
The revision of the guidelines for trans-European energy infrastructure Absent
The EU’s public health strategy post-COVID-19 For
A comprehensive Union policy on preventing money laundering and terrorist financing – the Commission’s Action Plan and other recent developments For
The Chemicals Strategy for Sustainability For
European Parliament recommendation to the Council and the Commission concerning the conclusion of an agreement, under negotiation, between the European Union and New Zealand on the exchange of personal data between the European Union Agency for Law Enforcement Cooperation (Europol) and the New Zealand authorities competent for fighting serious crime and terrorism Absent
A comprehensive European approach to energy storage Absent
The draft Commission implementing regulation amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, dimethomorph, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, formetanate, metribuzin, milbemectin… Absent
Objection pursuant to Rule 112(2) and (3): Certain uses of chromium trioxide Absent
Mobilisation of the Contingency Margin in 2020: continuation of humanitarian support to refugees in Turkey Absent
Amending budget 5/2020: continuation of the support to refugees and host communities in response to the Syria crisis in Jordan, Lebanon and Turkey Absent
Guidelines for the employment policies of the Member States Absent

Rows per page: 20 40 100 200 All